id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-283903-e20v88ge	Davoodi, Lotfollah	Febuxostat therapy in outpatients with suspected COVID‐19: A clinical trial	2020-06-30		.txt	text/plain	3121	194	46	BACKGROUND: The aim of this clinical trial was to evaluate the effects of febuxostat (FBX) in comparison with hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest CT findings in outpatients with moderate symptoms of COVID‐19 infection. The measured variables were needs to hospitalization, clinical and laboratory data including fever, cough, breathing rate, C‐Reactive Protein level, lymphocytes count at onset of admission and was well as at 5 days of treatments. On admission, fever (66.7%), cough (87%), tachypnea (44.4%), dyspnea (35%), elevated CRP value (94.4%) and lung involvement according to chest CT (100%) were documented in enrolled patients with insignificant difference between FBX and HCQ groups. In adult outpatients with moderate COVID‐19 infection, the effectiveness of FBX and HCQ was not different in terms of resolution of clinical manifestations, laboratory tests and lung CT findings. This clinical trial was conducted to assess the effects of FBX and hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest CT findings of patients with COVID-19 infection.	./cache/cord-283903-e20v88ge.txt	./txt/cord-283903-e20v88ge.txt